Class I Phosphatidylinositol 3-Kinases
"Class I Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits.
| Descriptor ID |
D058534
|
| MeSH Number(s) |
D08.811.913.696.620.500.100.100 D08.811.913.696.620.500.200.100 D12.776.476.162
|
| Concept/Terms |
Class I Phosphatidylinositol 3-Kinases- Class I Phosphatidylinositol 3-Kinases
- Class I Phosphatidylinositol 3 Kinases
- Class I Phosphatidylinositol 3-Kinase
- Class I Phosphatidylinositol 3 Kinase
- Phosphatidylinositol 3-Kinase, Class I
- Phosphatidylinositol 3 Kinase, Class I
|
Below are MeSH descriptors whose meaning is more general than "Class I Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Class I Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Class I Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Class I Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Class I Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-d and -?. Front Immunol. 2021; 12:718621.
-
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
-
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clin Cancer Res. 2019 02 15; 25(4):1156-1164.
-
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow. Expert Rev Anticancer Ther. 2017 Mar; 17(3):271-279.
-
The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. J Virol. 2014 Sep; 88(18):10673-9.
-
Acquired microcephaly in blepharophimosis-ptosis-epicanthus inversus syndrome because of an interstitial 3q22.3q23 deletion. Pediatr Neurol. 2014 Jun; 50(6):636-9.
-
Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis. Mol Cell Biol. 2014 Apr; 34(7):1363-77.
-
Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer. 2012 May; 51(5):480-9.
-
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res. 2010 May 15; 70(10):3996-4004.
-
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol. 2009 Nov 01; 183(9):5673-84.